Our CEO, Dr James Garner, sat down with CommSec’s Tom Piotrowski recently to discuss the company’s recent $4 million capital raising as well as key data readouts from Kazia’s clinical trials.
In the interview, Dr Garner discusses:
- The reasons behind the timing of the capital raising and why it was important to have the raise supported by specialist institutional investors.
- The Company’s recent efficacy data from its Cantrixil trial in ovarian cancer and the significance of treating patients in the later stages of the disease.
- The upcoming release of first efficacy data from Kazia’s phase II study of GDC-0084 in glioblastoma, expected in November.
- Kazia’s recent win in the inaugural ANZLF Trans-Tasman Innovation + Growth Awards.
Watch the interview here:
For more information on Kazia’s recent capital raise, read the ASX Announcement here https://www.asx.com.au/asxpdf/20191028/pdf/449y8r78nvpst0.pdf.
